Do IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy?

• Nuvation Bio Inc. announced that new long-term analyses from its pivotal Phase 2 TRUST-I and TRUST-II trials of IBTROZI (taletrectinib) in adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, originally scheduled for presentation at WCLC and ESMO in 2026, were subsequently presented and posted on its website.

• The upcoming detailed subgroup efficacy and safety readouts for IBTROZI, building on its June 2025 US FDA approval, give investors additional clinical context on how this next-generation ROS1 inhibitor performs across different real-world patient segments.

• We'll now examine how these long-term TRUST-I and TRUST-II data presentations for IBTROZI may influence Nuvation Bio's broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Nuvation Bio Investment Narrative Recap

To own Nuvation Bio, you need to believe IBTROZI can anchor a sustainable oncology franchise while safusidenib eventually matures into a second growth pillar. The new long term TRUST-I and TRUST-II subgroup data do not appear to change the near term focus on U.S. IBTROZI uptake and global approvals, nor the key risk that future ROS1 competitors or access hurdles could pressure this core revenue engine.

The most relevant recent announcement is the FDA's acceptance of an sNDA for IBTROZI, which already incorporates updated TRUST-I and TRUST-II data as of August 2025. Together with the upcoming WCLC and ESMO presentations, this reinforces that maturing real world and subgroup evidence for IBTROZI sits at the heart of both the upside case and the dependency risk around this single product.

Yet investors should also weigh how IBTROZI's class wide safety concerns, including liver toxicity, ILD and QTc prolongation, could influence...

Read the full narrative on Nuvation Bio (it's free!)

Nuvation Bio's narrative projects $445.1 million revenue and $86.3 million earnings by 2029. This requires 46.0% yearly revenue growth and a $232.3 million earnings increase from -$146.0 million today.

Uncover how Nuvation Bio's forecasts yield a $12.33 fair value , a 100% upside to its current price.

Exploring Other Perspectives

Before this update, the most bearish analysts were still modeling about US$391.5 million of 2029 revenue and US$83.9 million of earnings, yet they focused on how IBTROZI's growth depends on evolving RNA testing and ex U.S. partnerships, reminding you that reasonable people can look at the same drug and see very different futures that may need revisiting after these new data.